William Mariner Greenman Sells 447,757 Shares of Cerus (NASDAQ:CERS) Stock

Cerus Corporation (NASDAQ:CERS) CEO William Mariner Greenman sold 447,757 shares of the company’s stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $1.66, for a total value of $743,276.62. Following the transaction, the chief executive officer directly owned 4,998,493 shares in the company, valued at approximately $8,297,498.38. This trade represents a 8.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

William Mariner Greenman also recently made the following trade(s):

• On Friday, March 6th, William Mariner Greenman sold 78,187 shares of Cerus stock. The shares were sold at an average price of $2.01, for a total value of $157,155.87.

Cerus Price Performance

Shares of NASDAQ:CERS opened at $1.80 on Wednesday. Cerus Corporation has a twelve month low of $1.12 and a twelve month high of $2.96. The stock’s 50 day moving average is $2.28 and its 200-day moving average is $1.88. The company has a quick ratio of 1.17, a current ratio of 1.73 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $345.91 million, a price-to-earnings ratio of -22.50 and a beta of 1.51.

Cerus (NASDAQ:CERS) last announced its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.01) EPS for the quarter, meeting analysts’ consensus estimates of ($0.01). Cerus had a negative net margin of 7.58% and a negative return on equity of 26.09%. The business had revenue of $64.58 million during the quarter, compared to analyst estimates of $59.31 million. Sell-side analysts forecast that Cerus Corporation will post -0.08 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on CERS shares. Wall Street Zen downgraded Cerus from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Zacks Research lowered Cerus from a “hold” rating to a “strong sell” rating in a report on Thursday, March 12th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Cerus in a research report on Monday, January 12th. One equities research analyst has rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce”.

Institutional Trading of Cerus

A number of institutional investors have recently modified their holdings of CERS. Cibc World Markets Corp bought a new position in Cerus in the 4th quarter worth approximately $25,000. MML Investors Services LLC bought a new stake in Cerus during the 4th quarter valued at $37,000. Caitong International Asset Management Co. Ltd lifted its position in shares of Cerus by 68.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 18,712 shares of the biotechnology company’s stock worth $39,000 after acquiring an additional 7,603 shares in the last quarter. Bingham Private Wealth LLC bought a new position in shares of Cerus in the fourth quarter worth $40,000. Finally, CIBC Bancorp USA Inc. bought a new position in shares of Cerus in the third quarter worth $31,000. 78.37% of the stock is currently owned by hedge funds and other institutional investors.

Cerus News Roundup

Here are the key news stories impacting Cerus this week:

• Positive Sentiment: Cerus named COO Vivek Jayaraman as President & Chief Executive Officer effective July 1, 2026, with current CEO William “Obi” Greenman becoming Executive Chairman — a clear, pre‑announced succession that typically reduces leadership uncertainty. Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer
• Positive Sentiment: Large institutional investors have been increasing positions recently (notably AQR, UBS and Millennium), which can support liquidity and signal professional investor interest.
• Neutral Sentiment: The company disclosed executive compensation adjustments tied to the leadership change; these may be neutral-to-slightly-positive if they align incentives, but they could also increase near‑term dilution depending on grant size and vesting. Compensation Changes
• Negative Sentiment: Multiple insiders sold sizable blocks around $1.66: CEO William Greenman (~447,757 shares), incoming CEO/COO Vivek Jayaraman (~165,200), CFO Kevin Green (~127,544), Richard Benjamin (~101,740) and Chrystal Jensen (~113,008). Collective insider liquidations of this scale can create short‑term downward pressure and raise questions about timing or liquidity needs. CEO SEC Filing Benjamin SEC Filing
• Negative Sentiment: Analyst coverage is mixed-to-negative: recent downgrades (Wall Street Zen cut buy→hold; Zacks to strong sell) leave the consensus at a “Reduce” rating, which can limit upside from new buyers until sentiment improves.

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.